Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Protalix BioTherapeutics (PLX) Income from Continuing Operations (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Income from Continuing Operations data on record, last reported at 2355000.0 in Q3 2025.

  • For Q3 2025, Income from Continuing Operations fell 27.22% year-over-year to 2355000.0; the TTM value through Sep 2025 reached 5394000.0, up 156.38%, while the annual FY2024 figure was 2932000.0, 43.83% down from the prior year.
  • Income from Continuing Operations reached 2355000.0 in Q3 2025 per PLX's latest filing, up from 164000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 16209000.0 in Q2 2023 and bottomed at 11369000.0 in Q2 2021.
  • Average Income from Continuing Operations over 5 years is 1093526.32, with a median of 3131000.0 recorded in 2023.
  • The widest YoY moves for Income from Continuing Operations: up 2433.33% in 2021, down 500.34% in 2021.
  • A 5-year view of Income from Continuing Operations shows it stood at 8056000.0 in 2021, then tumbled by 139.85% to 3210000.0 in 2022, then tumbled by 87.1% to 6006000.0 in 2023, then skyrocketed by 208.13% to 6494000.0 in 2024, then plummeted by 63.74% to 2355000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 2355000.0 in Q3 2025, 164000.0 in Q2 2025, and 3619000.0 in Q1 2025.